Study of Lenalidomide in Combination With Sunitinib to Evaluate the Safety and Efficacy in Patients With Renal Cell Carcinoma

Stopped early · Phase 1/Phase 2

Conditions studied: Renal Cell Carcinoma

In brief

The purpose of this study was to determine the maximum tolerated dose, safety, and effectiveness of lenalidomide (CC-5013) administered in combination with sunitinib as treatment for patients with renal cell carcinoma.

Key facts

Study ID

NCT00975806

Run by

Celgene

People needed

16

Starts

2009-09-01

Expected to finish

2011-10-01

Last updated by the study team

2019-11-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Metastatic Renal Cell Carcinoma.
• Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1.

You may not qualify if…

• Prior chemotherapy.
• Prior treatment with lenalidomide, thalidomide, pomalidomide, or sunitinib.
• Laboratory values outside normal ranges.
• Myocardial infarction (MI) within past 12 months.
• Current congestive heart failure.

Where it is running

• University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan, United States
• Cleveland Clinic Main Campus — Cleveland, Ohio, United States
• Tennessee Oncology — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.